

Filed on behalf of: Abraxis Biosciences, LLC

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

CIPLA LTD.  
Petitioner,

v.

ABRAXIS BIOSCIENCE, LLC  
Patent Owner.

---

IPR2018-00162; IPR2018-00163; IPR2018-00164  
U.S. Patent Nos. 8,138,229; 7,820,788; and 7,923,536

---

**DECLARATION OF DAVID OUPICKY, Ph.D.**

## TABLE OF CONTENTS

I. INTRODUCTION .....	1
II. BACKGROUND & QUALIFICATIONS.....	1
III. BASIS OF OPINIONS .....	4
IV. LEGAL STANDARDS USED.....	6
A. Anticipation.....	6
B. Obviousness .....	7
V. THE ABRAXIS PATENTS.....	9
VI. CLAIM CONSTRUCTION.....	13
VII. STATEMENTS.....	14
A. Summary of Opinions .....	14
B. The patents in suit are not anticipated by Desai (GROUND I) .....	16
1. Desai does not literally disclose a ratio of “about 9:1” or “9:1”.....	16
2. Desai does not inherently disclose a ratio of 9:1 .....	18
(a) Desai states that Example 1 produces a final product with a ratio of 13.3:1 .....	19
(b) Dr. Desai provided additional evidence showing a loss of paclitaxel during manufacturing .....	27
(c) A POSA would expect loss of paclitaxel in view of the references in the Peppas Decl. and in view of Kadima .....	29
C. The Abraxis Patent claims would not have been obvious over the cited references .....	30
1. The claims would not have been obvious over Desai alone (GROUND II.A).....	30
(a) Desai does not expressly or inherently disclose a final ratio of 9:1 or about 9:1 ...	31
(b) A POSA would not have been motivated to adjust the ratios in Desai with a reasonable expectation of success.....	31
(c) A POSA would not have been motivated to adjust the Capxol™ ratio with a reasonable expectation of success.....	34
(d) The benefits of albumin teach away from reducing the albumin-to-paclitaxel ratio	40
2. The Abraxis Patent claims would not have been obvious over Desai in combination with Kadima and Liversidge (GROUND II.B).....	44
(a) None of the references teach the “about 9:1” or “9:1” final ratios .....	45
(b) Kadima teaches away from reducing the ratio from 13.3:1 to 9:1.....	48
(c) A POSA would not be motivated to reduce the ratio to 9:1 based on cost savings	50
(d) A POSA Would Have No Reason To Combine Desai with Kadima With A Reasonable Expectation Of Success .....	52

Filed on behalf of: Abraxis Biosciences, LLC

(e) A POSA Would Have No Reason To Combine Desai with Liversidge With A Reasonable Expectation Of Success .....	52
3. Claim 20 of the '229 would not have been obvious (GROUNDS III.A AND III.B) ...	54
4. Secondary considerations support nonobviousness .....	54
VIII. DECLARATION .....	58

Filed on behalf of: Abraxis Biosciences, LLC

I, David Oupicky, Ph.D., hereby declare and state as follows:

**I. INTRODUCTION**

1. I submit this declaration on behalf of Abraxis Bioscience, LLC (“Abraxis” or “Patent Owner”), Patent Owner of U.S. Pat. Nos. 7,820,788 (“the ’788 patent”), 7,923,536 (“the ’536 patent”), and 8,138,229 (“the ’229 patent”) (collectively, “the Abraxis Patents”) to provide my opinions on certain matters in connection with the petitions for inter partes reviews filed by Cipla Ltd. (“Cipla” or “Petitioner”) in case nos. IPR2018-00162, IPR2018-00163, and IPR2018-00164 (collectively, the “Cipla IPR Petitions”).

**II. BACKGROUND & QUALIFICATIONS**

2. My areas of expertise include formulation development of macromolecular and particulate delivery systems of small molecule drugs and therapeutic nucleic acids using self-assembly, bioconjugation, and encapsulation methods. The main focus of my research is the design of novel polymer-based systems for improved delivery and therapeutic efficacy of combination treatments.
3. My research laboratories at the University of Nebraska Medical Center and China Pharmaceutical University currently work on the development of

injectable anti-metastatic self-assembled polymers and nanoparticles as well as nanoparticles for improved drug delivery in the treatment of inflammatory bowel disease, pulmonary fibrosis, and kidney injury. My research centers on multiple aspects related to the chemical synthesis, pharmaceutical formulation and characterization, and in vitro and in vivo assessment of delivery and efficacy in relevant disease models.

4. I received an M.S. in Polymer Engineering from the Institute of Chemical Technology in Prague, Czech Republic in December 1993 and a Ph.D. in Macromolecular Chemistry from the Institute of Macromolecular Chemistry of the Czech Academy of Sciences in May 1999. From 1999 to 2002, I was a postdoctoral fellow in gene delivery at the CRC Institute for Cancer Studies at the University of Birmingham, United Kingdom.
5. I am currently appointed as the Parke-Davis Professor of Pharmaceutics and Co-Director of the Center for Drug Delivery and Nanomedicine in the Department of Pharmaceutical Sciences at the University of Nebraska Medical Center. I am also appointed as part-time Changjiang Scholar Chair Professor at China Pharmaceutical University in Nanjing, China.
6. Previously, I was an Assistant Professor (2002-2007) and an Associate Professor (2007-2013) in the Department of Pharmaceutical Sciences at

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.